Histogenics Announces Key Additions to Management Team

WALTHAM, Mass.--(BUSINESS WIRE)--Histogenics Corp., a late stage company developing novel tissue repair solutions initially targeting orthopedics, today announced the addition of two new members to its management team. Stephen Kennedy, previously with Genzyme, was added as Senior Vice President of Manufacturing, Operations, and Supply Chain, and Vladimir Scerbin, previously with Covidien, was added as Vice President of Clinical Affairs.

"As a late stage company developing an orthopedic implant that involves regenerative and cellular medicine technologies, the combined skills that both Stephen and Vladimir bring to the table will be critical moving forward," said Peter Greenleaf, Chief Executive Officer of Histogenics. "Our near term goal is to move the NeoCart Phase 3 clinical trial forward and get it fully enrolled as quickly as possible. We feel our management team is poised to do that."

Stephen Kennedy joins the team as Senior Vice President of Manufacturing, Operations, and Supply Chain and brings more than 30 years of experience in biological manufacturing and process development. Most recently, Mr. Kennedy served as the Executive Vice President of Research and Development at Mascoma Corporation, a provider of leading technology for the conversion of biomass to fuels and chemicals. Prior to this, Mr. Kennedy held positions at the Massachusetts Institute of Technology and Genzyme Corporation.

Vladimir Scerbin joins the team as the new Vice President of Clinical Affairs. Prior to joining Histogenics, Scerbin served as Vice President of International Clinical Affairs at Covidien, a global healthcare products company. At Covidien, Scerbin expanded and optimized the efficiency of the international clinical affairs function. Prior to Covidien, Mr. Scerbin held positions at Confluent Surgical Incorporated and Boston Scientific Corporation.

The Company's lead program, NeoCart®, is an investigational personalized cartilage tissue implant to treat knee injuries. The proprietary procedure developed by Histogenics uses regenerative medicine technology to create personalized hyaline-like cartilage tissue from a patient's own cells, which may potentially result in a durable, long-lasting patient response.

About Histogenics

Histogenics is a late stage company developing novel tissue repair solutions initially targeting orthopedics. We leverage the latest advances in molecular biology, materials sciences and tissue engineering to create innovative products to help patients maintain an active lifestyle. Our lead product program, NeoCart®, is a personalized cartilage tissue implant. For more information visit www.histogenics.com.


Histogenics Corp.
Cory Tromblee, 781-235-3060
[email protected]


Suggested Articles

Journey Colab launches with $3 million from Apollo Projects to develop a pipeline of psychedelic compounds through a new development model.

Forma's lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with relapsed or refractory acute myeloid leukemia.

A type of white blood cell known as a granulocyte secretes growth factors that help axons of the central nervous system regenerate, researchers found.